Besponsa and Phenytoin Sodium

• Generic Name: inotuzumab ozogamicin
• Dosage Forms: injection, powder, lyophilized, for solution
• Other Brand Names: Besponsa

Besponsa is a monoclonal antibody linked to a chemotherapy drug. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.

Besponsa is used to treat a certain type of acute lymphocytic leukemia that has come back or has not responded after prior chemotherapy.

Besponsa may also be used for purposes not listed in this medication guide.

• Generic Name: phenytoin
• Dosage Forms: injection, solution
• Other Brand Names: Dilantin, Dilantin Infatabs, Phenytek, Phenytoin Sodium, Prompt

Management of generalized tonic-clonic (grand mal) seizures.

Management of partial seizures with complex symptomatology (psychomotor and temporal lobe seizures).

Not recommended for treatment of pure absence (petit mal) seizures since the drug may increase frequency of these seizures, but may be used in conjunction with other anticonvulsants when mixed seizure types are present.

Prevention and treatment of seizures occurring during and following neurosurgery.

Used IV for treatment of status epilepticus; however, use may be limited by its slow onset of action and need for slow administration.

Benzodiazepines (e.g., diazepam, lorazepam, midazolam) are considered drugs of choice for initial treatment of status epilepticus; IV phenytoin (or fosphenytoin) may be used as a second-line agent if seizures continue.

Concurrent administration with an IV benzodiazepine or short-acting barbiturate will usually be necessary for rapid control of seizures.

Fosphenytoin appears to be better tolerated than phenytoin, and some experts state that fosphenytoin is preferred when both drugs are available.

Has been used IV for treatment of cardiac arrhythmias, particularly ventricular arrhythmias, in patients who do not respond to conventional antiarrhythmic agents or cardioversion. However, current use as an antiarrhythmic agent is limited by the drug's narrow therapeutic window, multiple drug interactions, and adverse effect profile.

Has been used IV for treatment of arrhythmias caused by cardiac glycoside intoxication, especially in the presence of AV block, because the drug improves conduction through the AV node.